查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790306

干癣性关节炎治疗市场规模、份额和趋势分析报告：按药物类别、类型、给药途径、地区和细分市场预测，2025 年至 2030 年

Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

干癣性关节炎治疗市场摘要

2024 年全球干癣性关节炎治疗市场价值估计为 113.5 亿美元，预计到 2030 年将达到 199.1 亿美元，2025 年至 2030 年的复合年增长率为 9.8%。新产品的推出、前景看好的产品线、消费者意识的显着提高以及疾病负担的增加预计将成为推动市场成长的一些因素。

干癣性关节炎是一种与银屑病相关的慢性退化性疾病。如果不及时、适当地治疗，该疾病可能导致不可逆的关节损伤。虽然确切的致病因素尚不清楚，但研究表明，近40%的病例与遗传因素有关。

干癣性关节炎有时会被误诊为类风湿性关节炎或痛风。然而，随着消费者意识的提高，以及私人和公共机构组织的多项宣传活动，预计误诊和误治的发生率将降低。此外，治疗费用的上涨以及部分药物的副作用预计将抑制市场成长。

生物製药的标靶作用和生物相似药的出现，正在为银屑病关节炎的治疗带来重大的模式转移。然而，消费者对安全性和疗效均有提升且经济实惠的药物的需求，可能会对市场动态产生正面影响。

改善新兴市场的医疗基础设施并扩大保险覆盖范围也至关重要。亚太和拉丁美洲国家正迅速改善其医疗体系，并扩大高成本生物製药的可近性。随着这些市场的成熟，它们为跨国和国内製药商提供了新的机会，使其能够覆盖先前服务不足的人群。

目录

第一章调查方法与范围

第二章执行摘要

第三章干癣性关节炎治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 干癣性关节炎治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章干癣性关节炎治疗市场：药物类别估计和趋势分析

  • 药品类别细分仪表板
  • 干癣性关节炎治疗市场：药物类别差异分析
  • 全球干癣性关节炎治疗市场规模及趋势分析（依药物类别，2018-2030 年）
  • NSAIDs
  • DMARD
  • 生物製药
  • 其他的

第五章干癣性关节炎治疗市场：类型估计和趋势分析

  • 类型细分仪表板
  • 干癣性关节炎治疗市场：类型变异分析
  • 全球干癣性关节炎治疗市场规模及趋势分析（2018-2030）
  • 处方笺
  • 非处方药

第六章干癣性关节炎治疗市场：给药途径估计与趋势分析

  • 给药途径细分仪表板
  • 干癣性关节炎治疗市场：给药途径变异分析
  • 全球干癣性关节炎治疗市场规模及趋势分析（依给药途径，2018-2030 年）
  • 外用
  • 口服
  • 注射

第七章干癣性关节炎治疗市场：区域估计和趋势分析

  • 区域市场仪表板
  • 2024 年及 2030 年区域市场占有率分析
  • 各地区连续生物加工市场：关键要点
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • Pfizer, Inc.
    • UCB SA
Product Code: GVR-2-68038-990-6

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.

Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.

Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • NSAIDs
  • DMARD
  • Biologics
  • Others
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Prescriptions
  • OTC
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical
  • Oral
  • Injectable
  • Regional Outlook (Revenue, USD Million, 2018 - 2026)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Type outlook
    • 2.2.3. Route of Administration
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Psoriatic Arthritis Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
  • 4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. DMARDs
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
  • 5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prescriptions
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. OTC
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Segment Dashboard
  • 6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Topical
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. AbbVie Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Amgen Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Services, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bristol-Myers Squibb Company
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Eli Lilly and Company
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Pfizer, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. UCB S.A.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 3 Global psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 4 Global psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 5 Global psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 6 North America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 7 North America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 8 North America psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 9 North America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 10 U.S. psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 11 U.S. psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 12 U.S. psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 13 Canada psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 14 Canada psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 15 Canada psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 16 Mexico psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 17 Mexico psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 18 Mexico surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 19 Europe psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 20 Europe psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 21 Europe psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 22 Europe psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 23 Germany psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 24 Germany psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 25 Germany psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 26 UK psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 27 UK psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 28 UK psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 29 France psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 30 France psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 31 France psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 32 Italy psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 33 Italy psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 34 Italy psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 35 Spain psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 36 Spain psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 37 Spain psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 38 Asia Pacific psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 39 Asia Pacific psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 40 Asia Pacific psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 41 Asia Pacific psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 42 China psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 43 China psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 44 China psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 45 Japan psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 46 Japan psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 47 Japan psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 48 India psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 49 India psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 50 India psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 51 South Korea psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 52 South Korea psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 53 South Korea psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 54 Australia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 55 Australia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 56 Australia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 57 Latin America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 58 Latin America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 59 Latin America surgical ablation market, by type (USD Million) 2018 - 2030
  • Table 60 Latin America laparoscopic ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 61 Latin America percutaneous ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 62 Latin America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 63 Brazil psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 64 Brazil psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 65 Brazil surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 66 Argentina psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 67 Argentina psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 68 Argentina surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 69 MEA psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 70 MEA psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 71 MEA psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 72 MEA psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 73 South Africa psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 74 South Africa psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 75 South Africa psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 76 Saudi Arabia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 77 Saudi Arabia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 78 Saudi Arabia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 79 UAE psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 80 UAE psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 81 UAE psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Psoriatic arthritis treatment market: market outlook
  • Fig. 10 Psoriatic arthritis treatment competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Psoriatic arthritis treatment market driver impact
  • Fig. 16 Psoriatic arthritis treatment market restraint impact
  • Fig. 17 Psoriatic arthritis treatment market strategic initiatives analysis
  • Fig. 18 Psoriatic arthritis treatment market: Drug Class movement analysis
  • Fig. 19 Psoriatic arthritis treatment market: Drug Class outlook and key takeaways
  • Fig. 20 NSAIDs market estimates and forecast, 2018 - 2030
  • Fig. 21 DMARDs market estimates and forecast, 2018 - 2030
  • Fig. 22 Biologics market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Psoriatic arthritis treatment Market: Type movement Analysis
  • Fig. 25 Psoriatic arthritis treatment market: Type outlook and key takeaways
  • Fig. 26 Prescriptions market estimates and forecasts, 2018 - 2030
  • Fig. 27 OTC market estimates and forecasts,2018 - 2030
  • Fig. 28 Psoriatic arthritis treatment market: Route of Administration movement analysis
  • Fig. 29 Psoriatic arthritis treatment market: Route of Administration outlook and key takeaways
  • Fig. 30 Topical market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oral market estimates and forecasts,2018 - 2030
  • Fig. 32 Injectable market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global psoriatic arthritis treatment market: Regional movement analysis
  • Fig. 34 Global psoriatic arthritis treatment market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 39 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 42 France market estimates and forecasts, 2018 - 2030
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 46 China market estimates and forecasts, 2018 - 2030
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 48 India market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030